These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Björkdahl O; Dohlsten M; Sjögren HO Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Shimizu K; Thomas EK; Giedlin M; Mulé JJ Cancer Res; 2001 Mar; 61(6):2618-24. PubMed ID: 11289139 [TBL] [Abstract][Full Text] [Related]
7. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986 [TBL] [Abstract][Full Text] [Related]
8. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
10. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
11. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Davila E; Kennedy R; Celis E Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660 [TBL] [Abstract][Full Text] [Related]
12. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination]. Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746 [TBL] [Abstract][Full Text] [Related]
13. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. Li Y; McGowan P; Hellström I; Hellström KE; Chen L J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929 [TBL] [Abstract][Full Text] [Related]
14. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine]. Ma J; Wang YL; Hu HM; Fox BA; Si LS Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138 [TBL] [Abstract][Full Text] [Related]
15. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887 [TBL] [Abstract][Full Text] [Related]
19. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Kurzawa H; Wysocka M; Aruga E; Chang AE; Trinchieri G; Lee WM Cancer Res; 1998 Feb; 58(3):491-9. PubMed ID: 9458095 [TBL] [Abstract][Full Text] [Related]
20. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]